Funds from the deal will be used to support the US market introduction and commercialization of the Irvine, Calif.-based company’s SuperSaturated Oxygen Therapy system designed to treat patients with acute myocardial infarction once the system wins FDA premarket approval.
TherOx said that it also recently released results from a study of its SSO2 Therapy system which confirmed the safety and effectiveness of the device in the treatment of anterior acute myocardial infarction patients who have undergone percutaneous coronary intervention procedures within six hours of experiencing AMI symptoms.
“We appreciate the ongoing support from our existing investor, Zoll Medical Corporation, as our positive discussions with the FDA continue and our PMA appears to be in the final phase of review. We look forward to the time when we can provide this important new therapy to physicians and their patients who experience typically debilitating large anterior AMIs,” TherOx prez & CEO Kevin Larkin said in a press release.
This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.
ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.
Take a look at our full agenda.
Use the code "TRACKS" to save 15% on the cost of registration.